All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @laurenlhale on Instagram · 13s|Watch on Instagram
Full video transcriptClick to expand

Auto-generated transcript of @laurenlhale's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Hi, hi, hi, with the lonely couch,
  2. 0:02Lay your, lay your, lay your,
  3. 0:04Eey, you're back with the girl in couch,
  4. 0:06Lay your, lay your, lay your, no!

@laurenlhale's perimenopause claims need context

Lauren Hale

Instagram creator

107.1K viewsView on Instagram

Quick answer

The video's caption references the dismissal of perimenopausal symptoms in women, a pattern documented in clinical literature showing inadequate provider training in menopause care. The TRT category tag suggests the content may have been moving toward testosterone use in perimenopausal women, an area with emerging but limited evidence outside of hypoactive sexual desire disorder. No specific clinical claims could be extracted from the available transcript due to audio capture issues.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @laurenlhale's perimenopause claims need context, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@laurenlhale's perimenopause claims need context is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@laurenlhale's perimenopause claims need context" from Lauren Hale. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The video's caption references the dismissal of perimenopausal symptoms in women, a pattern documented in clinical literature showing inadequate provider training in menopause care.

The reason this review is not generic is the source wording and the canonical claim label "trt this post is inspired by the 3 most common things i m told." In this clip, the useful excerpt is: "Hi, hi, hi, with the lonely couch, Lay your, lay your, lay your, Eey, you're back with the girl in couch, Lay your, lay your, lay your, no!" That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Fewer than 25% of ob-gyn residency programs provide adequate menopause education, per Faubion et al.
People who land here are usually comparing the Testosterone claim with perimenopausehealth, perimenopausesupport, and perimenopauserelief.
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The video's caption references the dismissal of perimenopausal symptoms in women, a pattern documented in clinical literature showing inadequate provider training in menopause care.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The video's caption references the dismissal of perimenopausal symptoms in women, a pattern documented in clinical literature showing inadequate provider training in menopause care. The TRT category tag suggests the content may have been moving toward testosterone use in perimenopausal women, an area with emerging but limited evidence outside of hypoactive sexual desire disorder. No specific clinical claims could be extracted from the available transcript due to audio capture issues.
  • Up to 80% of women experience vasomotor symptoms like hot flashes during perimenopause, per Kaunitz and Manson (2021, JAMA), making dismissal of these symptoms clinically indefensible.
  • Fewer than 25% of ob-gyn residency programs provide adequate menopause education, per Faubion et al. (2019, Menopause), which directly contributes to women being undertreated or dismissed.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Up to 80% of women experience vasomotor symptoms like hot flashes during perimenopause, per Kaunitz and Manson (2021, JAMA), making dismissal of these symptoms clinically indefensible.
  • Fewer than 25% of ob-gyn residency programs provide adequate menopause education, per Faubion et al. (2019, Menopause), which directly contributes to women being undertreated or dismissed.
  • Perimenopausal anxiety and mood changes have documented biological mechanisms, including estradiol-driven shifts in serotonin and GABA receptor activity, per Soares (2014, Menopause). These are not psychosomatic.
  • Testosterone is not FDA-approved for women in the United States. Off-label use has evidence support for sexual dysfunction specifically, not as a broad perimenopause treatment.
  • The Menopause Society (formerly NAMS) maintains a certified provider directory for women seeking clinicians with specific, current training in menopause and perimenopause care.
  • Hormone therapy guidelines were significantly overcorrected after the 2002 Women's Health Initiative study. Current evidence supports individualized hormone therapy for many perimenopausal women when appropriately indicated.
  • No specific medical claims could be verified from this video's transcript due to audio capture issues. Assessments here are based on the caption context and category classification only.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @laurenlhale actually say?

Honestly? Not much that can be fact-checked. The transcript captured for this video is essentially garbled audio, likely a music intro or upload artifact, with no coherent medical or health claims recorded. The caption, however, tells a clearer story. Lauren frames this as a response to three common things women on social media tell her, specifically around being dismissed or told their symptoms are "all in your head." That framing, at least, is worth examining on its own merits.

The hashtags point toward perimenopause symptom relief and testosterone replacement therapy, which suggests the video was likely heading into territory around hormonal interventions for perimenopausal women. Hot flashes and anxiety are specifically tagged. Without a clean transcript, we cannot fact-check specific claims, but we can address what the caption implies and what the category context suggests she was building toward.

Does the science back this up?

The core premise embedded in her caption, that women's perimenopausal symptoms are routinely dismissed as psychological, is well-supported by research. This is not a controversial fringe position.

A 2021 study by Kaunitz and Manson published in JAMA found that vasomotor symptoms like hot flashes affect up to 80% of women during the menopause transition, yet significant gaps in clinical recognition and treatment persist. Separately, a 2019 survey published in Menopause by Faubion et al. found that fewer than 25% of ob-gyn residency programs provided adequate menopause education, which helps explain why so many women report being dismissed by their providers.

The "it's all in your head" dismissal has real consequences. Perimenopausal anxiety, sleep disruption, and cognitive changes have biological mechanisms, including fluctuating estradiol levels affecting serotonin and GABA receptor activity (Soares, 2014, Menopause). These are not imagined. The frustration Lauren references from her followers reflects a documented gap in care, not a conspiracy theory.

What did they get wrong (or right)?

Based solely on what we can assess, the framing in the caption gets it right. Women are disproportionately undertreated for perimenopausal symptoms. That part holds up.

Where things get more complicated is the category tag: testosterone replacement therapy. Testosterone for perimenopausal and postmenopausal women is a legitimate area of clinical interest, but it is not FDA-approved for women in the United States. The Endocrine Society's 2019 clinical practice guidelines (Davis et al., Journal of Clinical Endocrinology and Metabolism) support testosterone use for hypoactive sexual desire disorder in postmenopausal women, but note the evidence base for other symptoms like fatigue, mood, and cognitive fog is still inconclusive.

If this video was building toward testosterone as a broad fix for perimenopause symptoms, that would be an overreach. There is real promise, but the science does not yet support recommending it for non-sexual symptoms with confidence. Any creator in this space should be careful about implying otherwise.

What should you actually know?

Perimenopause is a real, physiologically driven transition and dismissing its symptoms as psychological is both inaccurate and harmful. That said, treatment decisions, including whether hormone therapy of any kind is appropriate, require individualized clinical evaluation.

Hormone therapy, including estrogen, progesterone, and in some cases testosterone, has a legitimate evidence base for specific perimenopausal and menopausal symptoms. But "hormone optimization" as a broad marketing concept often outpaces what the studies actually support. The Women's Health Initiative scare of the early 2000s overcorrected many clinicians toward under-prescribing; the pendulum has since swung back, but nuance still matters.

If you're experiencing hot flashes, anxiety, sleep disruption, or other symptoms in your 40s, the first step is a provider who takes those symptoms seriously. The Menopause Society (formerly NAMS) maintains a provider directory for clinicians with specific menopause training. You deserve better than being told to push through it, but you also deserve accurate information about what treatments actually do.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Lauren Hale · Instagram creator

107.1K views on this video

This post is inspired by the 3️⃣ most common things I’m told by women on social media (so I know a lot of you may have heard these too). The way women are told to suffer through the symptoms or that t

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about up to 80% of women experience vasomotor symptoms like hot?

Up to 80% of women experience vasomotor symptoms like hot flashes during perimenopause, per Kaunitz and Manson (2021, JAMA), making dismissal of these symptoms clinically indefensible.

What does the video say about fewer than 25% of ob-gyn residency programs provide adequate menopause?

Fewer than 25% of ob-gyn residency programs provide adequate menopause education, per Faubion et al. (2019, Menopause), which directly contributes to women being undertreated or dismissed.

What does the video say about perimenopausal anxiety?

Perimenopausal anxiety and mood changes have documented biological mechanisms, including estradiol-driven shifts in serotonin and GABA receptor activity, per Soares (2014, Menopause). These are not psychosomatic.

What does the video say about testosterone?

Testosterone is not FDA-approved for women in the United States. Off-label use has evidence support for sexual dysfunction specifically, not as a broad perimenopause treatment.

What does the video say about the menopause society (formerly nams) maintains a certified provider directory?

The Menopause Society (formerly NAMS) maintains a certified provider directory for women seeking clinicians with specific, current training in menopause and perimenopause care.

What does the video say about hormone therapy guidelines were significantly overcorrected after the 2002 women's?

Hormone therapy guidelines were significantly overcorrected after the 2002 Women's Health Initiative study. Current evidence supports individualized hormone therapy for many perimenopausal women when appropriately indicated.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Lauren Hale, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.